scholarly journals Meropenem-Induced Neutropenia in a Neonate

2016 ◽  
Vol 21 (4) ◽  
pp. 353-357 ◽  
Author(s):  
Joseph S. Van Tuyl ◽  
Aubrey N. Jones ◽  
Peter N. Johnson

Postmarketing surveillance has associated meropenem with the development of hematologic abnormalities, including agranulocytosis, neutropenia, and leukopenia, but the exact incidence in children is unknown. The case describes a full-term, 26-day-old neonate admitted for a sepsis workup. She was found to have a blood culture positive for Enterobacter cloacae and suspected meningitis and was initiated on meropenem 40 mg/kg/dose intravenously every 8 hours. On day 14 of antibiotic treatment, the patient developed an isolated neutropenia with an absolute neutrophil count of 288 cells/mm3. Meropenem was discontinued on hospital day 20, and a follow-up complete blood cell count 2 months later confirmed resolution of the hematologic abnormality. Clinicians should monitor complete blood cell counts diligently in children who receive large doses and prolonged courses of meropenem.

PEDIATRICS ◽  
1981 ◽  
Vol 68 (2) ◽  
pp. 305-305
Author(s):  
Walt Karniski

I remember reading Todd's article1 as a medical student and feeling that he had simplified medical practice considerably, by "proving" that a complete blood cell count (CBC) could accurately distinguish between any child with bacteremia and a child with a viral illness. The article by Baron and Fink2 brought that memory to mind again, and therefore necessitates words of caution. When considering the efficacy of a test, it is helpful to consider a two-by-two table as follows, in which the Baron and Fink data are presented:


2003 ◽  
Vol 127 (11) ◽  
pp. 1421-1423 ◽  
Author(s):  
Paul Valenstein ◽  
Molly Walsh

Abstract Context.—Timely reporting of outpatient tests can increase efficiency of care and improve customer satisfaction. Objectives.—We conducted a survey in 2002 to determine how quickly hospital-based laboratories turned around routine requests for 3 common assays and compared the results with a similar survey conducted in 1997. Design.—One hundred eighteen laboratories prospectively recorded the collection-to-verification turnaround time for 9252 complete blood cell counts (CBCs), 8832 thyroid tests, and 9193 basic metabolic panels. Results.—The median facility reported all test results by 7:00 am of the weekday immediately after the date of specimen collection. The bottom 10% of institutions reported 99% of CBCs and basic metabolic panels within 1 day and 60% of thyroid tests within 1 day. The 65 institutions that participated in both the 1997 and 2002 surveys showed significant overall improvement in turnaround time for all 3 types of tests (P < .001). In 2002, federal institutions had significantly slower turnaround times than nonfederal institutions for CBC tests (P < .001), thyroid tests (P = .03), and basic metabolic panels (P < .001). Other demographic and practice variables were not associated with turnaround time. Conclusion.—The turnaround time of routine outpatient tests appears to have improved between 1997 and 2002.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12014-e12014
Author(s):  
Elena Sperk ◽  
Cornelia Wersal ◽  
Christel Weiss ◽  
Anke Keller ◽  
Anette Kipke ◽  
...  

e12014 Background: After radiotherapy changes in blood cell counts (BCC) can be seen. Leukocytopenia may have a negative impact on the immune system, outcome and quality of life of breast cancer survivors. No reports on changes of the three blood cell lines (leukocytes=WBC, erythrocytes=RBC, thrombocytes=PLT) after IORT w/o whole breast radiotherapy (WBRT) in breast cancer patients have been reported. Methods: 256 patients had IORT during breast conserving surgery. In 198 patients WBRT (46-50Gy/2Gy) + IORT (20Gy) and in 58 patients IORT as accelerated partial breast irradiation=APBI (20Gy) was given. Preoperative BCC were used as baseline. In 214 patients BCC were available after 1-90 days, in 139 during the 1st year, in 86 in the 2nd, in 66 in the 3rd, in 51 in the 4th and in 34 in the 5th year of follow-up. Dunnett-tests were used to calculate adjusted p-values (p<0.05=significant). Results: After IORT/WBRT a decrease of WBC was seen during the 1st year. Afterwards no changes were seen. After IORT APBI no changes were seen during 5 years follow-up. RBC was decreased at all time points after IORT/WBRT, and through the 1st year after IORT APBI. PLT decreased during the 1st year and stayed low during 5 years after IORT/WBRT. No changes in PLT were seen after IORT APBI. Hemoglobin (HGB) decreased after 3 months, during the 1st and 5th year after IORT/WBRT. After IORT APBI, HGB decreased only during the 1st year and stayed stable during follow-up. Conclusions: Decreases of all blood cell lines were seen at least transiently after IORT/WBRT. PLT and RBC stayed decreased. After IORT APBI, HGB and RBC decreased only during the 1st year and WBC and PLT remained stable during the whole follow-up. [Table: see text]


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1609-1609
Author(s):  
Marie-Olivia Chandesris ◽  
Francine Garnache ◽  
Ludovic Lhermitte ◽  
Kheira Beldjord ◽  
Anne-Sophie Bedin ◽  
...  

Abstract Abstract 1609 Poster Board I-635 Purine analogues (2-chlorodeoxyadenosine: 2-CdA and 2'-deoxycoformycin: dCF) significantly improved the complete response (CR) rate and the overall survival of hairy cell leukaemia (HCL) but are usually not curative with about 40% relapse rate. We developed an 8 colors flow cytometry (8-FC) technique (CANTO IITM, BD Biosciences) to follow the blood minimal residual disease (MRD) and evaluated its clinical relevance. 34 patients diagnosed with HCL at the Necker University Hospital (France) were retrospectively evaluated on frozen blood samples taken at diagnosis to select the relevant markers for MRD analysis. MRD follow-up (106 samples) using 8-FC was compared to IgH PCR clonality, using consensus qualitative IgH FR1 and FR2 PCR and Genscan revelation, performed on the same samples. Several antibodies were tested. The phenotype of hairy cells (HC) appeared to be heterogeneous from one patient to another. After a first identification of HC on the basis of CD45high, CD3 negativity, CD19/CD20/CD103/CD25 (moderate to high) positivity and light chain isotype restriction, we tested the expression of CD123 and CD305 (LAIR-1). They were expressed in all cases with high intensity as defined by the mean fluorescence intensity ratio (MFIR) calculated by dividing the MFI of each marker by that of the isotypic control. They could distinct HC from normal B cells in 82% and 78% whereas CD103 and CD25 were expressed with a lesser intensity and were not relevant for MRD analysis in 30% and 22%. Therefore, we have chosen the 8 antibodies combination as follows: CD103FITC/CD305PE/CD19Percp Cy5.5/CD123APC/CD25PC7/CD3Alexa700/CD45Amcyan/CD20Pacific Blue which discriminates HC in 100%. This combination was used to define in all 34 patients a “hairy cell associated phenotype” based on the expression of at least 2 HCL associated markers. The specificity was assessed on 10 normal blood samples and Our 8-FC combination appeared very specific with a robust sensitivity of at least 1.10-4. The comparative analysis of blood CF versus molecular MRD analyses showed an overall concordance of 81%: 52 samples (49%) being negative and 35 samples (33%) being positive by both techniques. 19 samples (18%) were discordant. In all these cases, CF MRD was positive (levels ranging from 10-4 to 10-2) but IgH-PCR appeared polyclonal. These data demonstrate the higher sensibility of CF as already shown by others. We then looked for a clinical relevance of FC MRD follow-up in a cohort of 18 patients with normal blood cell counts after 2-CdA therapy (5 in first line and 13 after 2 to 8 previous therapies including purine analogues, splenectomy, interferon-á and others). A median of 4 samples by patient were tested and the median follow-up time was 44 months [18-84]. Two groups could be distinguished. (A) Patients (n=13) with a sustained negative FC MRD (<10-4). Nine patients were negative from the first sample taken at around 6 months post 2-CdA. A FC MRD relapse was observed in three of them at 32, 46 and 72 months after therapy. Four patients were positive for the first sample but became negative at around 1 year post 2-CdA and remained negative after a follow-up of at least 18 months. (B) Patients (n=5) remaining FC MRD positive (median of 3 samples). Three were treated for haematological relapse at 40, 48 and 49 months from 2-CdA therapy. Two kept normal blood cell counts after a follow-up of 38 and 60 months. These data suggest that the risk of relapse after 2-CdA therapy is lower in case of negative blood FC MRD (<10-4) obtained in the 12 months following therapy than in patients with sustained positive MRD (≥10-4). This should lead, at least, to a closer haematological and FC follow-up of the positive patients. A prolonged follow-up is required to determine if such patients would benefit from a complementary therapy. Finally, we propose modified NCI criteria of response as follows in table 1. Table 1 Modified NCI criteria of response. Abbreviations: N normal, PR partial response, VGPR very good PR. Progressive disease is the reappearance or exacerbation of disease-related signs (clinical +/- biological) after achieving any kind of response and relapse is the need for re-treatment. CR VGPR PR HCL-related symptoms 0 0 0 Organomegaly 0 0 Decrease ≥ 50% Blood cell counts N N - Correction ≥ 1 cytopenia - No decrease in any cell count HC on blood smear 0 0 0 Blood FC MRD - + + Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 98 (Supplement_4) ◽  
pp. 291-292
Author(s):  
Elle Rottman ◽  
Alisun N Watson ◽  
Catherine Buck ◽  
Tsungcheng Tsai ◽  
Jeffery J Chewning ◽  
...  

Abstract Complete blood cell counts have been used as a diagnostic tool across many animal species including swine. To investigate the factors that cause variation in complete blood cell count results, a total of 2,284 whole blood samples were collected from 2012 to 2019 in preweaning piglets (n = 518), nursery pigs (n = 1,704), and grower pigs (n = 60). Whole blood was collected into K2EDTA blood collection tubes and assayed using an automatic hematologic analyzer within 6 hours of collection. Data were analyzed by Mixed procedure of SAS with gender, parity group, and farrowing season as fixed effects. Body weight and age of pigs served as covariances. Farrowing season was grouped into summer (born during May to October) or winter (or November to April). Pigs that were born from first, second, and third parity, and four and above parity sows were assorted into parity group 1, 2 to 3, and 4+, respectively. Barrows had a greater concentration of total white blood cells (P &lt; 0.01), lymphocytes (P &lt; 0.01), and neutrophils (P &lt; 0.01) compared to gilts. Barrows had lower mean corpuscular volume (P = 0.03), mean corpuscular hemoglobin (P &lt; 0.01), and mean corpuscular hemoglobin concentration (P = 0.02) compared to gilts. Pigs that were farrowed in the winter season had a greater concentration of white blood cells (P = 0.01), neutrophils (P = 0.01), and the percentage of neutrophils (P = 0.03), but were lower in the percentage of lymphocytes (P = 0.03) compared to pigs farrowed during summer. Pigs born to parity four and above sows obtained a greater lymphocyte count (P = 0.01), percentage of neutrophils (P = 0.02), and percentage of lymphocytes (P = 0.01). We concluded that peripheral complete blood cells count results were affected by gender, farrowing season, and sow parity.


2021 ◽  
Vol 99 (Supplement_1) ◽  
pp. 167-168
Author(s):  
Kwangwook Kim ◽  
Yijie He ◽  
Cynthia Jinno ◽  
Seijoo Yang ◽  
Xunde Li ◽  
...  

Abstract The objective of this experiment was to investigate dietary supplementation of oligosaccharide-based polymer on blood profiles of weaned pigs experimentally infected with a pathogenic F18 Escherichia coli (E. coli). Forty-eight pigs (7.23 ± 1.11 kg BW) were individually housed in disease containment rooms and randomly allotted to one of four treatments with 12 replicate pigs per treatment. The four dietary treatments were a nursery basal diet (control), and 3 additional diets supplemented with 50 mg/kg Mecadox (AGP), 10 or 20 mg/kg of oligosaccharide-based polymer. The experiment lasted 18 d [7 d before and 11 d after the first inoculation (d 0)]. The doses of F18 E. coli inoculum were 1010 cfu/3 mL oral dose daily for 3 days. Blood samples were collected before E. coli inoculation (d 0), and on d 2, 5, 8, and 11 post-inoculation (PI). Total and differential blood cell count were analyzed by CBC test. All data were analyzed by ANOVA using the PROC MIXED of SAS with pig as the experimental unit. Supplementation of oligosaccharide-based polymer linearly (P &lt; 0.05) reduced white blood cell counts, neutrophils, eosinophils, and basophils on d 2 PI, and neutrophils on d 5 PI, compared with the control. No differences were observed in total and differential white blood cell counts among AGP and two oligosaccharide-based polymer treatments except that pigs fed with AGP had greater (P &lt; 0.05) lymphocytes on d 2 PI compared with pigs fed with oligosaccharide-based polymer diets. Supplementation of low dose oligosaccharide-based polymer or AGP reduced (P &lt; 0.05) red blood cell count and packed cell volume on d 2 PI, whereas inclusion of high dose oligosaccharide-based polymer or AGP reduced (P &lt; 0.05) packed cell volume on d 5 PI, compared with the control. In conclusion, supplementation of oligosaccharide-based polymer may alleviate the systemic inflammation caused by F18 E. coli infection.


2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Leonardo M. Bella ◽  
Isis Fieri ◽  
Fernando H. G. Tessaro ◽  
Eduardo L. Nolasco ◽  
Fernanda P. B. Nunes ◽  
...  

Background/Aims. The effects of cholecalciferol supplementation on the course of diabetes in humans and animals need to be better understood. Therefore, this study investigated the effect of short-term cholecalciferol supplementation on biochemical and hematological parameters in mice.Methods. Male diabetic (alloxan, 60 mg/kg i.v., 10 days) and nondiabetic mice were supplemented with cholecalciferol for seven days. The following parameters were determined: serum levels of 25-hydroxyvitamin D, phosphorus, calcium, urea, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, red blood cell count, white blood cell count (WBC), hematocrit, hemoglobin, differential cell counts of peritoneal lavage (PeL), and bronchoalveolar lavage (BAL) fluids and morphological analysis of lung, kidney, and liver tissues.Results. Relative to controls, cholecalciferol supplementation increased serum levels of 25-hydroxyvitamin D, calcium, hemoglobin, hematocrit, and red blood cell counts and decreased leukocyte cell counts of PeL and BAL fluids in diabetic mice. Diabetic mice that were not treated with cholecalciferol had lower serum calcium and albumin levels and hemoglobin, WBC, and mononuclear blood cell counts and higher serum creatinine and urea levels than controls.Conclusion. Our results suggest that cholecalciferol supplementation improves the hematological parameters and reduces leukocyte migration into the PeL and BAL lavage of diabetic mice.


2002 ◽  
Vol 87 (03) ◽  
pp. 421-425 ◽  
Author(s):  
Janet Pickering ◽  
Peter Elwood ◽  
Antony Bayer ◽  
Shah Ebrahim ◽  
Ian Baker

SummaryFibrinogen, plasma viscocity, and the white blood cell count predict ischaemic heart disease, but there is less certainty for their predictive power for ischaemic stroke. Studying stroke and ischaemic heart disease in the same cohort prospectively allows comparison of predictive strengths. The Caerphilly and Speedwell cohorts consist of a population sample of 4,860 men aged 45-59 years at recruitment who had baseline measurements of fibrinogen, plasma viscosity, and white blood cell counts. After 15-19 years of follow-up, men in the two cohorts experienced 312 ischaemic strokes and 557 ischaemic heart disease events. Mean fibrinogen, plasma viscosity and white blood cell counts differed significantly after adjustment for confounding factors between men with and without ischaemic heart disease, 0.25 g/l (95% CIs 0.18-0.32); 0.036 cp (95% CIs 0.027-0.044); 0.67 X 109/l (95% CIs 0.50-0.84) respectively. The same measurements showed no significant differences after adjustment for the same confounding factors for men with and without ischaemic stroke, 0.05 g/l (95% CIs -0.04-0.14); 0.008 cp (95% CIs -0.003-0.019); 0.16 X 109/l (95% CIs -0.06-0.38) respectively.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A373-A374
Author(s):  
Iryna Oleksandrivna Kostitska ◽  
Mykola Mykolayovych Ostrovskyi ◽  
Iryna Yaremivna Makoida ◽  
Olga Bogdanivna Molodovets ◽  
Lyudmyla Antonivna Babliuk ◽  
...  

Abstract The world medical community is strongly concentrated on the fight COVD-19, HIV/AIDS, tuberculosis. The combination of two or more concurrent nosologies is a major problem in patient management. Thus considering the abovementioned facts, we would like to focus your attention on such comorbidities as diabetes and tuberculosis. Patient M., 49 y.o., type 2 diabetes during 10 years. In July 2018, she consulted her physician and complained of non-productive mild cough, low-grade fever, fatigue, reduced workability. After the follow-up examination which involved chest X-ray and complete blood cell count, she was diagnosed with an abscess forming pneumonia in the right lower lobe and prescribed treatment with the use of broad-spectrum antibiotics according to the protocol. After the treatment, the patient’s condition has slightly improved, though the labile diabetes with frequent episodes of hypoglycemia and hyperglycemia, and cough still persisted. The level of HbA1C was 7.8%. At the patient’s request, she continued to receive: glimepiride 6 mg/day, metformin 1000 mg/day. Considering the patient’s general condition as gradual recovery the doctor has discharged the patient. In January 2019, the patient consulted a tuberculotherapist, because the cough persisted, the body temperature markers sometimes attained feverish indices, the general weakness increased. After the follow-up examination: complete blood cell count, chest X-ray, sputum smear microscopy, genetic-molecular study with GeneXpert-test and culture test on the BACTEC system, the patient was diagnosed with disseminated tuberculosis with bacterial excretion, susceptible. The patient received treatment according to the 2HRZE 4HR scheme. Results: the treatment was completed, whereas the cavern was preserved, the patient refused to undergo surgical treatment. After 7 months, the previous symptoms reappeared, after additional examination the patient was diagnosed with multi-drug resistant tuberculosis and was prescribed treatment with second-line agents for 20 months, and the patient was given insulin degludec/aspart at a daily dose of 64 IU. The therapy resulted in patient’s recovery, the cavern was closed, and compensation of diabetes was achieved: no episodes of hypoglycemia were recorded; the HbA1C - 6.5%. Analyzing the previous data it is necessary to note the mistakes that were made. The mismatch of clinical symptoms with the established diagnosis, the absence of a sputum smear for acid-resistant bacteria, apical localization of tuberculosis which is typical for patients with diabetes was not characteristic in this case, all these factors have led to an incorrect diagnosis at the primary level. At the beginning of tuberculosis treatment, the patient should be transferred to the correction of blood glucose levels with insulin and, if the cavern preserves, the patient should be prepared for its surgical removal.


2016 ◽  
Vol 179 (1) ◽  
pp. 166-169 ◽  
Author(s):  
Veronika Buxhofer-Ausch ◽  
Bettina Gisslinger ◽  
Martin Schalling ◽  
Andreas Gleiss ◽  
Ana-Iris Schiefer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document